Puma Biotechnology (PBYI) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 11, 2025, to elect eight directors, ratify KPMG LLP as auditor, and hold a say-on-pay vote for executive compensation.

• Board recommends voting FOR all proposals and nominees.

• Shareholders of record as of April 21, 2025, are eligible to vote; 49,630,717 shares outstanding.

• Proxy materials are available online and by mail, with multiple voting methods offered.

Voting matters and shareholder proposals

• Proposals include election of eight directors, auditor ratification, and advisory approval of executive compensation.

• Board unanimously recommends voting FOR all proposals.

• Shareholders can submit proposals for the 2026 meeting by December 29, 2025, and nominate directors per bylaw procedures.

Board of directors and corporate governance

• Board consists of eight members with an average tenure of 8.2 years and diverse backgrounds in biotech, finance, and commercialization.

• Seven of eight directors are independent; Alan H. Auerbach is not independent due to his executive role.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, Equity Incentive, and Research and Development.

• Lead Independent Director presides over executive sessions; all directors met attendance requirements.

• Board reviews its composition and independence annually, following NASDAQ and SEC standards.